|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lin28A/B-stimulated tumor growth is abrogated by SREBP-1 inhibition and by the impairment of the RNA binding properties of Lin28A/B, respectively.
|
31379107 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer.
|
31296258 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, our data show that SREBP-1 inhibition facilitated the antitumor effects of Sorafenib on HCC cells and xenograft tumors.
|
31511501 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SREBP-1 is critical for OGT-mediated regulation of cell survival and of lipid synthesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and tumor growth in vitro and in vivo.
|
29059153 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Altogether, these data define an AR/mTOR nuclear axis, in the context of prostate cancer, as a novel pathway regulating SREBF1 activity and citrate metabolism.<b>Implications:</b> The finding that an AR/mTOR complex promotes SREBF1 expression and activity enhances our understanding of the metabolic adaptation necessary for prostate cancer cell growth and suggests novel therapeutic approaches to target metabolic vulnerabilities in tumors.<i></i>.
|
29784665 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further demonstrate that TD26-mediated increase in lipogenesis and tumor cell proliferation was SREBP1 dependent.
|
29663480 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of SREBP1 is directly correlated with malignant transformation of tumors.
|
28356952 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FASN along with other lipogenesis enzymes, and SREBP-1 proteins were upregulated in TRAMP tumors compared to wild-type prostatic tissues.
|
28342983 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth.
|
26555173 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, depletion of SREBP1 could suppress lipid metabolism and tumor growth in vivo.
|
25589463 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SREBP-1 was expressed at significantly higher levels in patients with large tumor size, high histological grade and advanced tumor-node-metastasis (TNM) stage (p < 0.05).
|
24776759 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a xenograft SCID mouse model, SREBP1 silencing inhibited tumor growth in vivo and reduced the expression of SREBP1 downstream lipogenic genes at both the protein and mRNA levels.
|
23818099 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, we found that knockdown of SREBP1 expression in EC cells suppressed cell growth, reduced colonigenic capacity and slowed tumor growth in vivo.
|
22672904 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In our investigation, studies of GBM cell lines, xenograft models, and GBM clinical samples, including those from patients treated with the EGFR tyrosine kinase inhibitor lapatinib, uncovered an EGFRvIII-activated, PI3K/SREBP-1-dependent tumor survival pathway through the low-density lipoprotein receptor (LDLR).
|
22059152 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, our results of immunohistochemical analysis for human breast tumor specimens indicate that the expressions of both FAS and SREBP-1 were colocalized with hypoxic regions in the tumors.
|
18281474 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AI tumors expressed significantly higher levels of SREBP-1.
|
15026365 |
2004 |